HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tylenol/aspirin ad

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer & Specialty Pharmaceuticals touts concomitant acetaminophen and aspirin use with a "Buddy System" print ad appearing in the July 7 New England Journal of Medicine. The ad shows a box of St. Joseph's low-dose aspirin with the statement, "Contains the dosage recommended most by doctors for effective cardiac prevention." The product is paired with Tylenol Arthritis Pain, which "has not been shown to increase the risk of GI bleeding in people taking aspirin, the way NSAIDs sometimes can," copy notes. The ad echoes a 2004 campaign advocating Tylenol over ibuprofen for low-dose aspirin users (1"The Tan Sheet" April 5, 2004, p. 7)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel